LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.
- SPONTAN Phase II interim data confirms 10-minute median Tmax
- Definitive US commercial agreements signed for ROXUS telehealth and pharmacy
- OROFLOW intranasal study gains ethics approval for oesophageal motility disorders
- Strong cash position of A$19.6 million with no debt at June 2026
- Key milestones include FDA submission prep and US ROXUS launch in H2 2026
SPONTAN’s Rapid Absorption Validated in Phase II Interim Data
LTR Pharma (ASX:LTP) has delivered encouraging interim results from its SPONTAN Phase II clinical trial, showing a median time to maximum plasma concentration (Tmax) of just 10 minutes after intranasal administration. This contrasts sharply with the 60-minute median Tmax observed for oral vardenafil, the current standard treatment. The data, drawn from 27 subjects including a significant cohort aged 65 and over, also showed no repeat-dose accumulation and no serious adverse events, ticking key boxes for the FDA’s 505(b)(2) regulatory pathway. The final statistical analysis is due in Q3 2026, which will underpin regulatory engagement and prescribing information development.
Definitive US Commercial Deals Cement ROXUS Launch Framework
On the commercial front, LTR Pharma has secured binding agreements with Shed Holdings LLC and Strive Specialties Inc., establishing the twin pillars for ROXUS’s US launch. Shed, a direct-to-consumer telehealth platform, will provide patient acquisition and telehealth services via its men’s health brand Mavrox, committing to a minimum of 150,000 ROXUS prescriptions in the first year. Meanwhile, Strive Pharmacy has exclusive rights to fulfil ROXUS prescriptions through its Section 503A compounding platform across multiple states, offering nationwide distribution capability. These agreements, converted into definitive contracts in July, mark a critical shift from partner selection to execution, with technology transfer and manufacturing readiness now the focus. This commercialisation strategy supports a planned US launch in the second half of 2026, subject to launch-readiness conditions. The deal with Strive Pharmacy builds on the company’s recent definitive US manufacturing deal and the Shed agreement complements the telehealth partnership.
OROFLOW Expands Intranasal Platform Beyond Erectile Dysfunction
LTR Pharma is also branching out with OROFLOW, an intranasal spray targeting Oesophageal Motility Disorders (OMD). The company has received Human Research Ethics Committee approval for an investigator-initiated clinical study led by Dr Peter Wu at St George Motility Services. This marks the first clinical evaluation of LTR’s intranasal platform outside men’s health. The study aims to assess improvements in swallowing function and chest pain, potentially opening a new multi-billion-dollar market. While OROFLOW remains a longer-term opportunity, this development signals LTR Pharma’s intent to diversify its pipeline beyond its current focus areas. The ethics nod aligns with previous coverage of the OROFLOW ethics approval.
Financial Position Supports Near-Term Milestones
Financially, LTR Pharma ended the quarter with a robust A$19.6 million cash balance and zero debt. The quarter’s net operating cash outflow was A$4.4 million, primarily driven by research and development costs linked to the completed treatment phase of the SPONTAN study. Importantly, this R&D spend is not expected to represent a recurring quarterly run rate. The company also generated modest receipts from SPONTAN prescriptions under Australia’s Special Access Scheme, providing real-world data ahead of commercial launch. With this financial runway, LTR Pharma is well-positioned to advance FDA submission-enabling activities and execute the US commercial launch of ROXUS in H2 2026.
Bottom Line?
With clinical validation nearing completion and US commercial infrastructure locked in, LTR Pharma is poised for a pivotal commercial launch phase that will test its intranasal platform’s market traction.
Questions in the middle?
- Will the final SPONTAN Phase II data sustain the rapid absorption and safety profile seen in interim results?
- How quickly can LTR Pharma scale manufacturing and fulfilment to meet the 150,000-unit ROXUS target in the US?
- Could OROFLOW’s clinical study open a new therapeutic frontier or remain a longer-term pipeline play?